FDA ad­comm votes in fa­vor of Al­ny­lam's new in­di­ca­tion for On­pat­tro

The FDA’s Car­dio­vas­cu­lar and Re­nal Drugs Ad­vi­so­ry Com­mit­tee on Wednes­day vot­ed 9-3 in fa­vor of Al­ny­lam Phar­ma­ceu­ti­cals’ On­pat­tro (patisir­an) on whether its ben­e­fits out­weigh its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER